Star Therapeutics reported preliminary phase 1/2 data showing its once-monthly injection substantially reduced bleeding rates in patients with von Willebrand disease and has started dosing in a pivotal Phase 3 trial of VGA039. Company executives signaled they are weighing strategic options including an IPO to fund later-stage development. ASH presentations previewed the antibody’s efficacy signal and safety profile that supported the move into pivotal testing. The company outlined next steps to complete larger trials and discussions with regulators about endpoints that would support approval. Investors and partners will watch enrollment, pivotal endpoints, and capital plans; successful Phase 3 data could position Star for a competitive role in bleeding-disorder therapeutics.